Recombinant human erythropoietin in predialysis patients.
VS Lim - American Journal of Kidney Diseases: the Official …, 1991 - europepmc.org
VS Lim
American Journal of Kidney Diseases: the Official Journal of the …, 1991•europepmc.orgThis report reviews the author's experience and the results of a multicenter study with regard
to the use of recombinant human erythropoietin (Epo) in predialysis patients. The data
demonstrate that Epo corrects anemia and improves quality-of-life assessment and exercise
capacity in patients who are not dialyzed, but who have renal insufficiency. The incidence of
hypertension was 22% in the Epo-treated subjects and 19% in the placebo group. Within the
Epo-treated group, there appears to be a greater frequency of hypertensive events in those …
to the use of recombinant human erythropoietin (Epo) in predialysis patients. The data
demonstrate that Epo corrects anemia and improves quality-of-life assessment and exercise
capacity in patients who are not dialyzed, but who have renal insufficiency. The incidence of
hypertension was 22% in the Epo-treated subjects and 19% in the placebo group. Within the
Epo-treated group, there appears to be a greater frequency of hypertensive events in those …
This report reviews the author's experience and the results of a multicenter study with regard to the use of recombinant human erythropoietin (Epo) in predialysis patients. The data demonstrate that Epo corrects anemia and improves quality-of-life assessment and exercise capacity in patients who are not dialyzed, but who have renal insufficiency. The incidence of hypertension was 22% in the Epo-treated subjects and 19% in the placebo group. Within the Epo-treated group, there appears to be a greater frequency of hypertensive events in those subjects receiving the higher dosages. The concern that Epo might accelerate the deterioration of renal function is not substantiated by several clinical studies.
europepmc.org
